DANIEL ROSS ROGERS
Pilots at Fortuna Ave, San Diego, CA
License number
California A4700869
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
1720 Fortuna Ave, San Diego, CA 92109
Professional information
Pyrrolidine Derivatives-Ccr-3 Receptor Antagonists
US Patent:
6166015, Dec 26, 2000
Filed:
Nov 18, 1999
Appl. No.:
9/442656
Inventors:
Daniel Harry Rogers - San Diego CA
John Saunders - San Diego CA
John Patrick Williams - San Diego CA
John Saunders - San Diego CA
John Patrick Williams - San Diego CA
Assignee:
Syntex (U.S.A.) Inc. - Palo Alto CA
International Classification:
A61K 3140, C07D20708, C07D40112, C07D40306
US Classification:
514243
Abstract:
This invention relates to certain 3-aminomethylpyrrolidine derivatives of Formula (I): ##STR1## that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
2,5-Substituted Pyrimidine Derivatives-Ccr-3 Receptor Antagonists
US Patent:
6984643, Jan 10, 2006
Filed:
Jul 1, 2003
Appl. No.:
10/611049
Inventors:
Daisy Joe Du Bois - Palo Alto CA, US
Long Mao - San Diego CA, US
Daniel Harry Rogers - San Diego CA, US
John Patrick Williams - San Diego CA, US
Long Mao - San Diego CA, US
Daniel Harry Rogers - San Diego CA, US
John Patrick Williams - San Diego CA, US
Assignee:
Roche Palo Alto LLC - Palo Alto CA
International Classification:
C07D 401/12, A61K 31/506, A31P 11/06
US Classification:
514256, 514274, 514275, 544316, 544332, 544335
Abstract:
Compounds of Formula (I):
wherein Aris aryl; Aris hydrogen, cycloalkyl, aryl or heteroaryl; Z is —C(═O) or a single bond; R, R, R, Rand Rare independently hydrogen or alkyl optionally substituted with hydroxy; alk is an alkylene chain of one to six carbon atoms; X is —O—, —NR(where Ris hydrogen or alkyl), (CRR)(where Rand Rare independently in each occurrence hydrogen or alkyl and m is an integer from 0 to 3), or —S(O)(wherein n is an integer from 0 to 2); or prodrugs thereof, and pharmaceutically acceptable salts thereof,
are inhibitors of CCR3 useful for treating eosinophil induced diseases such as asthma.
Novel Flavors, Flavor Modifiers, Tastants, Taste Enhancers, Umami Or Sweet Tastants, And/Or Enhancers And Use Thereof
US Patent:
2012020, Aug 9, 2012
Filed:
Dec 23, 2011
Appl. No.:
13/336272
Inventors:
Catherine Tachdjian - San Diego CA, US
Andrew P. Patron - San Marcos CA, US
Farid Bakir - San Diego CA, US
Qing Chen - San Diego CA, US
Vincent Darmohusodo - Encinitas CA, US
Stephen Terrence Hobson - San Marcos CA, US
Xiaodong Li - San Diego CA, US
Ming Qi - Shanghai, CN
Daniel H. Rogers - San Diego CA, US
Guy Servant - San Diego CA, US
Xiao-Qing Tang - San Diego CA, US
Mark Zoller - La Jolla CA, US
Daivd Wallace - San Diego CA, US
Amy Xing - San Diego CA, US
Klaus Gubernator - Del Mar CA, US
Andrew P. Patron - San Marcos CA, US
Farid Bakir - San Diego CA, US
Qing Chen - San Diego CA, US
Vincent Darmohusodo - Encinitas CA, US
Stephen Terrence Hobson - San Marcos CA, US
Xiaodong Li - San Diego CA, US
Ming Qi - Shanghai, CN
Daniel H. Rogers - San Diego CA, US
Guy Servant - San Diego CA, US
Xiao-Qing Tang - San Diego CA, US
Mark Zoller - La Jolla CA, US
Daivd Wallace - San Diego CA, US
Amy Xing - San Diego CA, US
Klaus Gubernator - Del Mar CA, US
Assignee:
SENOMYX, INC. - San Diego CA
International Classification:
A61K 8/49, C07D 317/68, C07F 9/655, C07C 235/46, C07D 405/12, C07D 319/18, C07D 321/10, C07D 307/85, C07D 263/56, C07D 241/24, A61K 8/55, A61K 8/42, A61K 47/22, A61K 47/24, A61K 47/18, A61Q 11/00, A23L 1/226
US Classification:
424 54, 426535, 426536, 426537, 426538, 549436, 549220, 564176, 5462837, 548526, 549362, 549350, 549467, 548217, 544406, 514788, 514785
Abstract:
The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, —savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.
Flavors, Flavor Modifiers, Tastants, Taste Enhancers, Umami Or Sweet Tastants, And/Or Enhancers And Use Thereof
US Patent:
8124121, Feb 28, 2012
Filed:
Oct 23, 2008
Appl. No.:
12/257017
Inventors:
Catherine Tachdjian - San Diego CA, US
Andrew P. Patron - Encinitas CA, US
Farid Bakir - San Diego CA, US
Qing Chen - San Diego CA, US
Vincent Darmohusodo - San Diego CA, US
Stephen Terrence Hobson - San Diego CA, US
Xiaodong Li - Oceanside CA, US
Ming Qi - Shanghai, CN
Daniel H. Rogers - San Diego CA, US
Guy Servant - San Diego CA, US
Xiao-Qing Tang - San Diego CA, US
Mark Zoller - La Jolla CA, US
David Wallace - San Diego CA, US
Amy Xing - San Diego CA, US
Klaus Gubernator - Del Mar CA, US
Andrew P. Patron - Encinitas CA, US
Farid Bakir - San Diego CA, US
Qing Chen - San Diego CA, US
Vincent Darmohusodo - San Diego CA, US
Stephen Terrence Hobson - San Diego CA, US
Xiaodong Li - Oceanside CA, US
Ming Qi - Shanghai, CN
Daniel H. Rogers - San Diego CA, US
Guy Servant - San Diego CA, US
Xiao-Qing Tang - San Diego CA, US
Mark Zoller - La Jolla CA, US
David Wallace - San Diego CA, US
Amy Xing - San Diego CA, US
Klaus Gubernator - Del Mar CA, US
Assignee:
Senomyx, Inc. - San Diego CA
International Classification:
A61K 47/00, A61K 31/4965
US Classification:
424439, 51425505, 514616, 514357
Abstract:
The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, —savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.
Raf Kinase Inhibitors
US Patent:
2012017, Jul 12, 2012
Filed:
Mar 19, 2012
Appl. No.:
13/424111
Inventors:
Jill E. WOOD - Hamden CT, US
Hanno Wild - Wuppertal, DE
Daniel H. Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CT, US
Yolanda Caringal - Branford CT, US
Robert Dally - East Haven CT, US
Wendy Lee - Hamden CT, US
Roger A. Smith - Madison CT, US
Cheri Blum - Alameda CA, US
Hanno Wild - Wuppertal, DE
Daniel H. Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CT, US
Yolanda Caringal - Branford CT, US
Robert Dally - East Haven CT, US
Wendy Lee - Hamden CT, US
Roger A. Smith - Madison CT, US
Cheri Blum - Alameda CA, US
International Classification:
A61K 31/381, A61K 31/4155, A61K 31/437, A61K 31/34, A61K 31/40, A61K 31/404, A61K 31/427, A61K 31/4025, C07D 333/38, C07D 417/12, C07D 409/12, C07D 307/68, C07D 207/34, C07D 471/04, A61P 35/00, A61K 31/433
US Classification:
514303, 514447, 514363, 514407, 514444, 514472, 514423, 514415, 514370, 514422, 549 69, 548140, 549 59, 5483657, 548468, 548196, 548527, 549480, 548532, 546119
Abstract:
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Raf Kinase Inhibitors
US Patent:
2005025, Nov 17, 2005
Filed:
Jun 10, 2005
Appl. No.:
11/149332
Inventors:
Jill Wood - Hamden CT, US
Hanno Wild - Wuppertal, DE
Daniel Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CT, US
Yolanda Caringal - Bran Ford CT, US
Robert Dally - East Haven CT, US
Wendy Lee - Hamden CT, US
Roger Smith - Madison CT, US
Cheri Blum - Alameda CA, US
Hanno Wild - Wuppertal, DE
Daniel Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CT, US
Yolanda Caringal - Bran Ford CT, US
Robert Dally - East Haven CT, US
Wendy Lee - Hamden CT, US
Roger Smith - Madison CT, US
Cheri Blum - Alameda CA, US
International Classification:
A61K031/433, A61K031/416, A61K031/381
US Classification:
514362000, 514406000, 514444000, 514447000
Abstract:
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Inhibition Of Raf Kinase Activity Using Aryl Ureas
US Patent:
6187799, Feb 13, 2001
Filed:
May 22, 1998
Appl. No.:
9/083399
Inventors:
Jill E Wood - Hamden CT
Hanno Wild - Wuppertal, DE
Daniel H Rogers - San Diego CA
John Lyons - Moraga CA
Michael Katz - Wallingford CT
Yolanda Caringal - Branford CT
Robert Dally - East Haven CT
Wendy Lee - Hamden CT
Roger A. Smith - Madison CT
Cheri Blum - Alameda CA
Hanno Wild - Wuppertal, DE
Daniel H Rogers - San Diego CA
John Lyons - Moraga CA
Michael Katz - Wallingford CT
Yolanda Caringal - Branford CT
Robert Dally - East Haven CT
Wendy Lee - Hamden CT
Roger A. Smith - Madison CT
Cheri Blum - Alameda CA
Assignee:
Onyx Pharmaceuticals - Richmond CA
Bayer Corporation - West Haven CT
Bayer Corporation - West Haven CT
International Classification:
A61K 3138, C07D40900, C07D33342, C07D30702
US Classification:
514363
Abstract:
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Raf Kinase Inhibitors
US Patent:
2001000, Jul 5, 2001
Filed:
Jan 8, 2001
Appl. No.:
09/755060
Inventors:
Jill Wood - Hamden CT, US
Hanno Wild - Wuppertal, DE
Daniel Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CA, US
Yolanda Caringal - Branford CT, US
Robert Dally - Gast Haven CT, US
Wendy Lee - Hamden CT, US
Roger Smith - Madison CT, US
Cheri Blum - Alameda CA, US
Hanno Wild - Wuppertal, DE
Daniel Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CA, US
Yolanda Caringal - Branford CT, US
Robert Dally - Gast Haven CT, US
Wendy Lee - Hamden CT, US
Roger Smith - Madison CT, US
Cheri Blum - Alameda CA, US
Assignee:
BAYER CORPORATION and ONYX PHARMACEUTICALS West Haven, CT and Richmond, CA, respectively
International Classification:
A61K031/38, C07D409/00, C 07D 3 7/02, C07D333/42
US Classification:
514/363000, 514/371000, 514/397000, 514/407000, 514/414000, 514/444000, 548/140000, 548/196000, 548/315100, 548/365700, 548/465000, 549/059000, 549/069000, 549/480000
Abstract:
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Raf Kinase Inhibitors
US Patent:
2010006, Mar 11, 2010
Filed:
Nov 17, 2009
Appl. No.:
12/619878
Inventors:
Jill E. WOOD - Hamden CT, US
Hanno Wild - Wuppertal, DE
Daniel H. Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CT, US
Yolanda Caringal - Branford CT, US
Robert Dally - East Haven CT, US
Wendy Lee - Hamden CT, US
Roger A. Smith - Madison CT, US
Cheri Blum - Alameda CA, US
Hanno Wild - Wuppertal, DE
Daniel H. Rogers - San Diego CA, US
John Lyons - Moraga CA, US
Michael Katz - Wallingford CT, US
Yolanda Caringal - Branford CT, US
Robert Dally - East Haven CT, US
Wendy Lee - Hamden CT, US
Roger A. Smith - Madison CT, US
Cheri Blum - Alameda CA, US
International Classification:
A61K 31/381, A61P 35/00, A61K 31/433, A61K 31/4155, A61K 31/404, A61K 31/427, A61K 31/4025, A61K 31/40, A61K 31/341, A61K 31/437, C07D 333/36, C07D 417/12, C07D 409/12, C07D 307/68, C07D 471/04
US Classification:
514303, 514447, 514363, 514407, 514414, 514371, 514422, 514423, 514472, 549 69, 548140, 549 59, 548465, 548196, 548527, 549480, 546119
Abstract:
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Daniel Brian Rogers, San Diego CA - Lawyer
Address:
PO Box 85266, San Diego 92186
(619) 645-2283
(619) 645-2283
Licenses:
California - Active 1999
Education:
Thomas Jefferson School of Law
University of California - San Diego
University of California - San Diego